4 The ideal oral anticoagulant Oral, preferably once daily Rapid onset and offset of action Low propensity for food and drug interactions Fixed doses Wide therapeutic window Easy to use with no need for monitoring i Have antidote

8 Safety endpoints Main Major bleeding starting after the first blinded dose and 2 days after last dose Bleeding that was fatal, into a critical organ or required re-operation Extra-surgical-site site bleeding associated with a drop in hemoglobin 2 g/dl or requiring transfusion of 2 units blood Other Any bleeding on treatment* Non-major bleeding* Hemorrhagic wound complications* Cardiovascular adverse events Liver enzyme levels All endpoints were adjudicated centrally by independent, blinded committees *Up to 2 days after last dose of study medication

30 Contra-indications Rivaroxaban should not be taken by anyone who: is allergic to rivaroxaban or to any of the ingredients of the medication is bleeding excessively is pregnant or breast-feeding is taking certain medications such as ketoconazole, itraconazole, voriconazole, posaconazole, or ritonavir has a body lesion at risk of bleeding, including bleeding in the brain within the last 6 months has liver disease associated with an increased risk of bleeding

ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

About the RECORD Clinical Trial Program Fast facts RECORD was a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism

Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.

Living with a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) dabigatran (Pradaxa ) rivaroxaban (Xarelto ) apixaban (Eliquis ) Information for patients Produced and made available by the Western Australian

New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

Living with a New Oral Anticoagulant (NOAC) dabigatran (Pradaxa ) rivaroxaban (Xarelto ) apixaban (Eliquis ) Information for patients Produced and made available by the Western Australian Medication Safety

RIVAROXABAN Consumer Information Rivaroxaban is a medicine that is used to increase the time it takes for blood to clot. It belongs to a class of medicines called anticoagulants, which are sometimes also

Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre

Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.

News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

(Za-REL-toe) rivaroxaban Consumer Medicine Information WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Xarelto. It does not contain all the available information. It does not take

1 FULL REVIEW for treatment of deep vein thrombosis and pulmonary embolism, and for prevention of venous thromboembolism recurrence (riv-ah-rocks-ah-ban) An alternative to parenteral anticoagulation with

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered

Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment

(Za REL toe) rivaroxaban Consumer Medicine Information WHAT IS IN THIS LEAFLET This leaflet answers some common questions about It does not contain all the available information. It does not take the place

Drugs R D DOI 10.1007/s40268-015-0105-9 REVIEW ARTICLE Rivaroxaban: An Evaluation of its Cardiovascular Benefit Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically

Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary

Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new

Safety Information Card for Xarelto Patients 15mg Simply Protecting More Patients 20mg Simply Protecting More Patients Keep this card with you at all times Present this card to every physician or dentist

MEDICATION GUIDE XARELTO (zah-rel-toe) (rivaroxaban) Tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide

December 7, 2015 Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis XALIA is First Prospective Study to Confirm Benefit

A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose

Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

What You Need to KnowWhen Taking Anticoagulation Medicine What are anticoagulant medicines? Anticoagulant medicines are a group of medicines that inhibit blood clotting, helping to prevent blood clots.

Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac